Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03854721 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer
A Phase 1 study, sponsored by Vaxiion Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03854721 is a Phase 1 study that has completed, run by Vaxiion Therapeutics. The registered enrollment target is 6 participants.
The verdict
NCT03854721, a Phase 1 study, has completed, sponsored by Vaxiion Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the safety, tolerability and activity of VAX014 for Instillation (VAX014) in patients with low-grade Non-Muscle Invasive Bladder Cancer (NMIBC). VAX014 is a targeted oncolytic agent designed to kill tumor cells following instillation into the urinary bladder.
Interventions
- DRUG VAX014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-05-10 |
| Est. Completion | 2023-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03854721
The ClinicalTrials.gov registry entry for NCT03854721 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vaxiion Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VAX014 is the first listed.
NCT03854721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03854721 about?
NCT03854721 is a clinical study titled "A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer". The purpose of this research study is to evaluate the safety, tolerability and activity of VAX014 for Instillation (VAX014) in patients with low-grade Non-Muscle Invasive Bladder Cancer (NMIBC). VAX014 is a targeted oncolytic agent designed to kill tumor cells following instillation into the urinary...
What is the current status of trial NCT03854721?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2019-05-10. Estimated completion is 2023-03-01.
What interventions are being tested in trial NCT03854721?
The interventions under investigation include: VAX014 (DRUG).
Who is sponsoring clinical trial NCT03854721?
This trial is sponsored by Vaxiion Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.